Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A keto diet helped some people with hard-to-treat depression, a safer new blood thinner showed much less major bleeding than rivaroxaban in atrial fibrillation, mini dental implants stayed stable for 18 months, a near-painless wearable patch tracked vancomycin levels every 5 minutes, and researchers identified the body’s own molecule that flips on the STING immune alarm.

Good news: People with hard-to-treat depression felt a little better when they used a keto diet along with their usual medicine. This hints that food changes could help some people, with the right support.

A Ketogenic Diet for Treatment-Resistant Depression: A Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂🙂 (Uses regular foods and diet support that are available now, but it’s tough to follow and should be done with medical guidance.)

Good news: All implant options stayed in place for 18 months (no implant failures). That means smaller “mini” implants may still be a workable choice for some people who can’t get bigger implants.

A 1.5-year randomized controlled trial comparing standard-sized implants and two diameters of mini-implants immediately loaded by mandibular overdenture: radiographic outcomes, short-term survival, and success rate

Market readiness: 🙂🙂🙂🙂🙂 (Standard and mini dental implants plus overdenture care are already offered in the US; this study helps guide which approach is best.)

Good news: A new kind of blood thinner (abelacimab) caused much less serious bleeding than rivaroxaban in people with atrial fibrillation, including older adults. If bigger studies confirm this, stroke prevention could be safer.

Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial

Market readiness: 🙂🙂🙂 (Tested in a phase 2b human trial, but still needs phase 3 results and FDA review before routine use.)

Good news: Researchers tested a tiny needle patch that can measure drug levels every 5 minutes without lots of blood draws. In a small human pilot, it was safe and almost pain-free while tracking vancomycin, which could help doctors dose risky drugs more safely.

Pilot phase clinical trial of a wearable, electrochemical aptamer-based patch for continuous drug concentration measurement

Market readiness: 🙂🙂 (Early pilot test in a few healthy volunteers; needs bigger trials and product development before clinical use.)

Good news: Scientists found the body’s own molecule that turns on STING, an important immune “alarm system.” This could help researchers build new medicines that fight infections or calm harmful inflammation.

An endogenous ligand for the human STING pathway

Market readiness: 🙂 (Basic lab discovery; not yet a treatment or test you can get in the US.)

Thank you for taking the time to take care of yourself and your loved ones.